These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38958683)

  • 21. The impact of using SGLT-2 inhibitor on left ventricular longitudinal strain and NT-proBNP levels during six-month follow-up in diabetic patients with and without coronary artery disease with preserved ejection fraction.
    Biter HI; Cakal S; Cakal B; Aapaydin Z; Kilinc AY; Oguz H; Yildiz S; Ogur H; Belen E; Simsek E
    Kardiol Pol; 2024; 82(6):640-646. PubMed ID: 38767161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study.
    Thomsen RW; Knudsen JS; Kahlert J; Baggesen LM; Lajer M; Holmgaard PH; Vedin O; Ustyugova A; Sørensen HT
    J Am Heart Assoc; 2021 Jun; 10(11):e019356. PubMed ID: 34032121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of baseline ECG characteristics on changes in cardiac biomarkers and echocardiographic metrices after acute myocardial infarction treated with Empagliflozin.
    Benedikt M; Aziz F; Fröschl T; Strohhofer C; Kolesnik E; Tripolt N; Pferschy P; Wallner M; Bugger H; Zirlik A; Scherr D; Sourij H; von Lewinski D
    Sci Rep; 2024 Jul; 14(1):15083. PubMed ID: 38956086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empagliflozin after Acute Myocardial Infarction.
    Butler J; Jones WS; Udell JA; Anker SD; Petrie MC; Harrington J; Mattheus M; Zwiener I; Amir O; Bahit MC; Bauersachs J; Bayes-Genis A; Chen Y; Chopra VK; Figtree G; Ge J; Goodman SG; Gotcheva N; Goto S; Gasior T; Jamal W; Januzzi JL; Jeong MH; Lopatin Y; Lopes RD; Merkely B; Parikh PB; Parkhomenko A; Ponikowski P; Rossello X; Schou M; Simic D; Steg PG; Szachniewicz J; van der Meer P; Vinereanu D; Zieroth S; Brueckmann M; Sumin M; Bhatt DL; Hernandez AF
    N Engl J Med; 2024 Apr; 390(16):1455-1466. PubMed ID: 38587237
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
    Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
    Fitchett D; Inzucchi SE; Cannon CP; McGuire DK; Scirica BM; Johansen OE; Sambevski S; Kaspers S; Pfarr E; George JT; Zinman B
    Circulation; 2019 Mar; 139(11):1384-1395. PubMed ID: 30586757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of sodium-glucose cotransporter-2 inhibitors on cardiac structure remodeling and function: A meta-analysis of randomized controlled trials.
    Fan G; Guo DL
    Eur J Intern Med; 2023 Aug; 114():49-57. PubMed ID: 37062643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empagliflozin Effects in Patients with ST-Elevation Myocardial Infarction Undergoing Primary PCI: The EMI-STEMI Randomized Clinical Trial.
    Khani E; Aslanabadi N; Mehravani K; Rezaei H; Afsharirad H; Entezari-Maleki T
    Am J Cardiovasc Drugs; 2024 Sep; 24(5):673-684. PubMed ID: 38969953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular and cerebrovascular diseases: a meta-analysis of controlled clinical trials.
    Wang F; Li C; Cui L; Gu S; Zhao J; Wang H
    Front Endocrinol (Lausanne); 2024; 15():1436217. PubMed ID: 39247919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Empagliflozin in acute myocardial infarction: the EMMY trial.
    von Lewinski D; Kolesnik E; Tripolt NJ; Pferschy PN; Benedikt M; Wallner M; Alber H; Berger R; Lichtenauer M; Saely CH; Moertl D; Auersperg P; Reiter C; Rieder T; Siller-Matula JM; Gager GM; Hasun M; Weidinger F; Pieber TR; Zechner PM; Herrmann M; Zirlik A; Holman RR; Oulhaj A; Sourij H
    Eur Heart J; 2022 Nov; 43(41):4421-4432. PubMed ID: 36036746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of sodium-glucose co-transporter 2 inhibitors (SGLT2i) on N-terminal pro-B-type natriuretic peptide (NT-proBNP) level and structural changes following myocardial infarction: A systematic review and meta-analysis.
    Banjar S; Alharbi S; Omer I; Al Zaid N; Alghamdi A; Abuthiyab N; Alzahrani A
    Int J Cardiol; 2024 Sep; 410():132239. PubMed ID: 38852858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of empagliflozin in women and men with acute myocardial infarction: An analysis from the EMMY trial.
    Sourij C; Aziz F; Tripolt NJ; Siller-Matula J; Pferschy PN; Kolesnik E; Wallner M; Eyileten C; Postula M; Oulhaj A; Sourij H; von Lewinski D;
    Hellenic J Cardiol; 2024; 75():3-8. PubMed ID: 37236318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of empagliflozin: final results from the EMPRISE study.
    Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Schmedt N; Koeneman L; Déruaz-Luyet A; Paik JM; Patorno E
    Diabetologia; 2024 Jul; 67(7):1328-1342. PubMed ID: 38509341
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial.
    Anker SD; Butler J; Filippatos G; Khan MS; Marx N; Lam CSP; Schnaidt S; Ofstad AP; Brueckmann M; Jamal W; Bocchi EA; Ponikowski P; Perrone SV; Januzzi JL; Verma S; Böhm M; Ferreira JP; Pocock SJ; Zannad F; Packer M
    Circulation; 2021 Jan; 143(4):337-349. PubMed ID: 33175585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
    Santos-Gallego CG; Vargas-Delgado AP; Requena-Ibanez JA; Garcia-Ropero A; Mancini D; Pinney S; Macaluso F; Sartori S; Roque M; Sabatel-Perez F; Rodriguez-Cordero A; Zafar MU; Fergus I; Atallah-Lajam F; Contreras JP; Varley C; Moreno PR; Abascal VM; Lala A; Tamler R; Sanz J; Fuster V; Badimon JJ;
    J Am Coll Cardiol; 2021 Jan; 77(3):243-255. PubMed ID: 33197559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats.
    Oshima H; Miki T; Kuno A; Mizuno M; Sato T; Tanno M; Yano T; Nakata K; Kimura Y; Abe K; Ohwada W; Miura T
    J Pharmacol Exp Ther; 2019 Mar; 368(3):524-534. PubMed ID: 30552292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes.
    Sarak B; Verma S; David Mazer C; Teoh H; Quan A; Gilbert RE; Goodman SG; Bami K; Coelho-Filho OR; Ahooja V; Deva DP; Garg V; Gandhi S; Connelly KA; Yan AT
    Cardiovasc Diabetol; 2021 Oct; 20(1):200. PubMed ID: 34607574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis.
    Li X; Wu H; Peng H; Jiang H
    Front Endocrinol (Lausanne); 2022; 13():1078686. PubMed ID: 36589800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of empagliflozin on total myocardial infarction events by type and additional coronary outcomes: insights from the randomized EMPA-REG OUTCOME trial.
    Fitchett D; Zinman B; Inzucchi SE; Wanner C; Anker SD; Pocock S; Mattheus M; Vedin O; Lund SS
    Cardiovasc Diabetol; 2024 Jul; 23(1):248. PubMed ID: 38992713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
    Connelly KA; Mazer CD; Puar P; Teoh H; Wang CH; Mason T; Akhavein F; Chang CW; Liu MH; Yang NI; Chen WS; Juan YH; Opingari E; Salyani Y; Barbour W; Pasricha A; Ahmed S; Kosmopoulos A; Verma R; Moroney M; Bakbak E; Krishnaraj A; Bhatt DL; Butler J; Kosiborod MN; Lam CSP; Hess DA; Rizzi Coelho-Filho O; Lafreniere-Roula M; Thorpe KE; Quan A; Leiter LA; Yan AT; Verma S
    Circulation; 2023 Jan; 147(4):284-295. PubMed ID: 36335517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.